FTC Distorted Actavis Ruling In Generics Dispute, Impax Says
Impax Laboratories LLC set the stage for a broad Fifth Circuit fight with the Federal Trade Commission in the generic-drug maker's appeal of the agency's reverse-payment decision, accusing the commission Thursday...To view the full article, register now.
Already a subscriber? Click here to view full article